Nebenwirkungen · Retacrit
Retacrit 1 000 IU/0.3 mL solution for injection in pre-filled syringe Retacrit 2 000 IU/0.6 mL solution for injection in pre-filled syringe Retacrit 3 000 IU/0.9 mL solution for injection in pre-filled syringe Retacrit 4 000 IU/0.4 mL solution for injection in pre-filled syringe Retacrit 5 000 IU/0.5 mL solution for injection in pre-filled syringe Retacrit 6 000 IU/0.6 mL solution for injection in pre-filled syringe Retacrit 8 000 IU/0.8 mL solution for injection in pre-filled syringe Retacrit 10 000 IU/1 mL solution for injection in pre-filled syringe Retacrit 20 000 IU/0.5 mL solution for injection in pre-filled syringe Retacrit 30 000 IU/0.75 mL solution for injection in pre-filled syringe Retacrit 40 000 IU/1 mL solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 16
HOS-119591 · Präparat HOS-094973
MedDRA System Organ Adverse Reaction (Preferred Frequency Classification (SOC) Term Level) Blood and lymphatic system Pure red cell aplasia3, Rare disorders Thrombocythaemia Metabolism and nutrition Hyperkalaemia1 Uncommon disorders Immune system disorders Hypersensitivity3 Uncommon Anaphylactic reaction3 Rare Nervous system disorders Headache Common Convulsion Uncommon Vascular disorders Hypertension, Venous and Common arterial thrombosis2 Hypertensive crisis3 Not known Respiratory, thoracic and Cough Common mediastinal disorders Respiratory tract congestion Uncommon Gastrointestinal disorders Diarrhoea, Nausea, Vomiting Very common Skin and subcutaneous tissue Rash Common disorders Urticaria3 Uncommon Angioneurotic oedema3 Not known Musculoskeletal and Arthralgia, Bone pain, Common connective tissue disorders Myalgia, Pain in extremity Congenital, familial and Porphyria acute3 Rare genetic disorders General disorders and Pyrexia Very common administration site conditions Chills, Influenza like illness, Common Injection site reaction, Oedema peripheral Drug ineffective3 Not known Investigations Anti-erythropoietin antibody Rare positive
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-20T16:27:00Z · SHA-256 85c4780ee223a9afb0db74c1b931ee10d15ab69c223b49e059f55799c892bb2d · Passage e374ff88ac68015b5b51a1b53464479dc34b652700c34ea90c0725131aa61e38 · Zeichen 1973–4079 im Abschnitt